Breaks Categories: Stock Spotlights

ThursdayNov 11, 2021 12:46 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leveraging Partnerships to Facilitate TRP-8803’s Advancement

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently announced a collaboration with researchers at the University of Wisconsin-Madison as part of preparations toward planned phase 2b studies. Under the partnership, Dr. Paul Hutson, PharmD, and Dr. Christopher Nicholas, Ph.D., will support clinical pharmacology studies for TRP-8803, Tryp’s proprietary drug formulation with a novel route of administration. Once completed, the studies will provide additional regulatory support for TRP-8803. The pair will also serve as investigators on a clinical pharmacology study to evaluate the safety and pharmacokinetics of TRP-8803. “This partnership is the latest in a series of collaborations with scholars, institutions and…

Continue Reading

TuesdayNov 09, 2021 2:11 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Extending Proprietary Technology, Programs Beyond Traditional Diabetes Market

Nemaura Medical (NASDAQ: NMRD), a cutting-edge medical technology company, recently conducted the beta launch of MiBoKo, a new proprietary metabolic health program designed to utilize a non-invasive glucose sensor and an AI-based mobile application. The MiBoKo application is designed to measure and monitor the user’s metabolic health scores based on glucose tolerance and insulin resistance. The cutting-edge program provides users with personalized information by tracking their metabolism when the app and sensor are used in conjunction with one another. In addition to receiving real-time updates on their metabolic health scores, MiBoKo users will be eligible to receive weekly and monthly…

Continue Reading

TuesdayNov 02, 2021 2:45 pm

BioMedNewsBreaks – Why Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Is ‘One to Watch’

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. Founded in 2020 based on delivering to significant unmet need in the mental health and therapeutic treatment environments, Mydecine is dedicated to efficiently developing innovative first- and second-generation novel therapeutics to treat PTSD, addiction and other disorders. “The company currently has four lead drug candidates, which include various enhancements such as improved controllability, delivery mechanisms, safety, stability and shelf-life. The drug candidates are in clinical trials or in pre-trial stage as potential treatments to aid…

Continue Reading

MondayNov 01, 2021 11:39 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Way Through Unique Psychedelic Drug Development Focus

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is nearing the launch of a phase 2a clinical trial that aims to establish the value of its psychedelic drug candidate, TRP-8802, in treating chronic and severe eating disorders such as Prader-Willi Syndrome (“PWS”), hypothalamic obesity disorder resulting from the removal of a brain tumor, and binge eating dysfunction. Tryp also plans to execute phase 2b clinical trials for its proprietary psychedelic candidate TRP-8803 to evaluate its ability to penetrate the natural blood-brain barrier and effectively alleviate pain and addiction concerns, including targets for phantom limb pain and fibromyalgia. “Tryp’s product development moves beyond…

Continue Reading

FridayOct 29, 2021 1:38 pm

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leveraging CDA Technology for Critical Early Cancer Detection

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, since 2015 has commercially proven out its concepts through the development and sale of its cancer detection technology, Cancer Differentiation Analysis (“CDA”) for early detection of pre-cancerous disease and cancer. “The company has published numerous reports of clinical study results at major conferences, including ACSO conferences, and has been awarded over 100 patents globally. AnPac Bio is now able to make the claim that it is saving lives on a daily basis by detecting 26 different types of cancer very early, through the tens of…

Continue Reading

ThursdayOct 28, 2021 12:00 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Stands Distinct in Patient Support

Nemaura Medical (NASDAQ: NMRD), a company focused on providing digital and glucose monitoring solutions for patients dealing with diabetes, pays close attention to essential information and research that impacts the successful implementation of its solutions. Recently, the company tweeted about a study published by Dove Medical Press that included a survey of 105 participants with type 2 diabetes. The report indicated that most participants were interested in using electronic methods to communicate more with their doctors between visits. “These findings are particularly interesting to Nemaura, which has developed a proprietary technology that replaces traditional invasive methods of glucose monitoring that…

Continue Reading

FridayOct 22, 2021 12:34 pm

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Identifies Market Gap, Launches ‘Desire Project’

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF), a leader in advanced proprietary technology and research for psychedelics, recently launched its “Desire Project” to address and treat female hypoactive sexual desire disorder (“HSDD”) with MDMA-assisted psychotherapy. A first-of-its-kind study, the Desire Project, is targeting HSDD, a common sexual disorder characterized by a persistent, low sexual drive with emotional distress that is not associated with an existing medical or relationship problem. The study comprises some of the world’s leading researchers in female sexual desire and psychedelics. Through the Desire Project, MINDCURE hopes to tackle the challenges faced by women suffering from the…

Continue Reading

FridayOct 22, 2021 12:25 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Facilitating Improved Diabetes and Prediabetes Management

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing diagnostic devices and supporting personalized lifestyle coaching programs. Its flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible continuous glucose monitor designed to help people with diabetes and prediabetes manage their glucose levels. “Over 420 million people globally are currently living with diabetes, with prediabetic cases totaling almost three times that number,” reads a recent article. “Combining clinical research with patient-friendly technology and through its sugarBEAT product, Nemaura Medical seeks to provide a non-invasive, affordable and flexible method of blood glucose tracking for improved diabetes management.” To view…

Continue Reading

FridayOct 22, 2021 12:16 pm

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) Unique Platform Offering Comprehensive Blood Test Data, New Approach to Disease Screening

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has developed the Cancer Differentiation Analysis (“CDA”) technology — a proprietary approach to detect cancerous and pre-cancerous diseases. “CDA uses the blood’s natural biophysical properties to identify cancerous environments before tumors even form. The CDA platform, in which technology is combined with protein-based biomarker tests to obtain even more comprehensive information, can be used to obtain more comprehensive data and information,” explains a recent article. “Unlike most liquid-based cancer screening and detection methods, the CDA platform from AnPac Bio focuses on assessing the existing protein-based…

Continue Reading

FridayOct 22, 2021 12:02 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Well Qualified to Provide Global Insight into Medical Cannabis

RYAH Group (CSE: RYAH), a connected device and big data and technology company, in a recent blog post provided insight into the cannabis medical space in Brazil, the largest South American country both in size and population, boasting a GDP per capita of $15,388. A recent article that contains excerpts from the post notes that medical cannabis in Brazil may face some steep political hurdles but that the waves of reform are slowly making it possible for more patients to access more medicine. “While the country has faced challenges, RYAH notes that Brazil seems poised at the top of a…

Continue Reading